Kindler H - Search Results

1

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.

Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG. Hassan R, et al. Among authors: kindler h. Clin Cancer Res. 2019 Oct 1;25(19):5787-5798. doi: 10.1158/1078-0432.CCR-19-0070. Epub 2019 Jul 1. Clin Cancer Res. 2019. PMID: 31263030 Free PMC article. Clinical Trial.

2

Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.

Kindler HL, Belani CP, Herndon JE 2nd, Vogelzang NJ, Suzuki Y, Green MR. Kindler HL, et al. Cancer. 1999 Nov 15;86(10):1985-91. Cancer. 1999. PMID: 10570422 Clinical Trial.

3

The role of gemcitabine in the treatment of malignant mesothelioma.

Kindler HL, van Meerbeeck JP. Kindler HL, et al. Semin Oncol. 2002 Feb;29(1):70-6. doi: 10.1053/sonc.2002.30232. Semin Oncol. 2002. PMID: 11836671 Review.

4

Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.

Mani S, Rudin CM, Kunkel K, Holmlund JT, Geary RS, Kindler HL, Dorr FA, Ratain MJ. Mani S, et al. Clin Cancer Res. 2002 Apr;8(4):1042-8. Clin Cancer Res. 2002. PMID: 11948111 Clinical Trial.

5

Malignant pleural mesothelioma.

Kindler HL. Kindler HL. Curr Treat Options Oncol. 2000 Oct;1(4):313-26. doi: 10.1007/s11864-000-0047-4. Curr Treat Options Oncol. 2000. PMID: 12057157 Review.

6

The pemetrexed/gemcitabine combination in pancreatic cancer.

Kindler HL. Kindler HL. Cancer. 2002 Aug 15;95(4 Suppl):928-32. doi: 10.1002/cncr.10755. Cancer. 2002. PMID: 12209673 Free article. Review.

7

A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.

Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ. Helft PR, et al. Clin Cancer Res. 2004 Jul 1;10(13):4363-8. doi: 10.1158/1078-0432.CCR-04-0088. Clin Cancer Res. 2004. PMID: 15240523 Clinical Trial.

8

Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.

Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, Humerickhouse R, André AK, Wang Q, Carr RA, Ratain MJ. Ryan CW, et al. Clin Cancer Res. 2004 Jul 1;10(13):4406-11. doi: 10.1158/1078-0432.CCR-04-0083. Clin Cancer Res. 2004. PMID: 15240529 Clinical Trial.

9

The emerging role of pemetrexed for the treatment of malignant mesothelioma.

Kindler HL. Kindler HL. Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):49-53. Oncology (Williston Park). 2004. PMID: 15339060 Free article. Review.

10

Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.

Rudin CM, Marshall JL, Huang CH, Kindler HL, Zhang C, Kumar D, Gokhale PC, Steinberg J, Wanaski S, Kasid UN, Ratain MJ. Rudin CM, et al. Clin Cancer Res. 2004 Nov 1;10(21):7244-51. doi: 10.1158/1078-0432.CCR-04-0642. Clin Cancer Res. 2004. PMID: 15534098 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

367 results

Search Page

Filters